Nagavarakishore Pillarsetty

Dr. Nagavarakishore Pillarsetty

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2016 in Nature
Verified
Journal Article
Closed access
PDF file
ARAnna Rodina
Anna Rodina
TWTai Wang
Tai Wang
PYPengrong Yan
Pengrong Yan
EGErica DaGama Gomes
Erica DaGama Gomes
MDMark P. S. Dunphy
Mark P. S. Dunphy
GCGabriela Chiosis
Gabriela Chiosis

25 September 2011 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
KMKamalika Moulick
Kamalika Moulick
JAJames H Ahn
James H Ahn
HZHongliang Zong
Hongliang Zong
ARAnna Rodina
Anna Rodina
LCLeandro Cerchietti
Leandro Cerchietti
GCGabriela Chiosis
Gabriela Chiosis

17 May 2003 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
KRKannan Raghuraman
Kannan Raghuraman
KKKavita K. Katti
Kavita K. Katti
LBLeonard J. Barbour
Leonard J. Barbour
NPNagavarakishore Pillarsetty
Nagavarakishore Pillarsetty
CBCharles L. Barnes
Charles L. Barnes
KKKattesh V. Katti
Kattesh V. Katti

28 October 2015 in Bioconjugate Chemistry
Verified
Journal Article
Open access
JMJan-Philip Meyer
Jan-Philip Meyer
JHJacob L. Houghton
Jacob L. Houghton
PKPaul Kozlowski
Paul Kozlowski
DADalya Abdel-Atti
Dalya Abdel-Atti
TRThomas Reiner
Thomas Reiner
JLJason S. Lewis
Jason S. Lewis
A first-of-its-kind 18F pretargeted PET imaging approach based on the bioorthogonal inverse electron demand Diels–Alder (IEDDA) reaction between tetrazine (Tz) and trans-cyclooctene (TCO) is presented. As proof-of-principle, a TCO-bearing immunoconjugate of the anti-CA19.9 antibody 5B1 and an Al[18F]NOTA-labeled tetrazine radioligand were harnessed for the visualization of CA19.9-expressing BxPC3 pancreatic cancer xenografts. Biodistribution and 18F-PET imaging data clearly demonstrate that this methodology effectively delineates tumor mass with activity concentrations up to 6.4 %ID/g at 4 h after injection of the radioligand.

26 September 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JNJames Nagarajah
James Nagarajah
MLMina Le
Mina Le
JKJeffrey A. Knauf
Jeffrey A. Knauf
GFGiuseppe Ferrandino
Giuseppe Ferrandino
CMCristina Montero-Conde
Cristina Montero-Conde
JFJames A. Fagin
James A. Fagin
Radioiodide (RAI) therapy of thyroid cancer exploits the relatively selective ability of thyroid cells to transport and accumulate iodide. Iodide uptake requires expression of critical genes that are involved in various steps of thyroid hormone biosynthesis. ERK signaling, which is markedly increased in thyroid cancer cells driven by oncogenic BRAF, represses the genetic program that enables iodide transport. Here, we determined that a critical threshold for inhibition of MAPK signaling is required to optimally restore expression of thyroid differentiation genes in thyroid cells and in mice with BrafV600E-induced thyroid cancer. Although the MEK inhibitor selumetinib transiently inhibited ERK signaling, which subsequently rebounded, the MEK inhibitor CKI suppressed ERK signaling in a sustained manner by preventing RAF reactivation. A small increase in ERK inhibition markedly increased the expression of thyroid differentiation genes, increased iodide accumulation in cancer cells, and thereby improved responses to RAI therapy. Only a short exposure to the drug was necessary to obtain a maximal response to RAI. These data suggest that potent inhibition of ERK signaling is required to adequately induce iodide uptake and indicate that this is a promising strategy for the treatment of BRAF-mutant thyroid cancer.

10 April 2023 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
Martin K. BakhtMartin K. Bakht
Martin K. Bakht
YYYasutaka Yamada
Yasutaka Yamada
SKSheng-Yu Ku
Sheng-Yu Ku
VVVaradha Balaji Venkadakrishnan
Varadha Balaji Venkadakrishnan
JKJoshua A. Korsen
Joshua A. Korsen
HBHimisha Beltran
Himisha Beltran